Tribogenics closes $6.2M Series A financing round

NewsGuard 100/100 Score

Tribogenics, a producer of innovative X-ray sources, announced today that it has closed a $6.2 million Series A financing round led by Founders Fund. The company previously received $2.5M in funding from Flywheel Ventures and other angel investors.

"We are excited to work with Founders Fund because they have a passion for building great companies that successfully pursue real innovation through disruptive technologies," said Dale Fox, President and CEO of Tribogenics. "This investment will help us accelerate development of our new X-ray sources that promise to dramatically influence a number of large markets."

"X-ray sources haven't experienced major innovation in almost a century. Advancing the state of the art advances discovery and we're delighted to help Tribogenics pursue their vision," said Bruce Gibney, partner at Founders Fund, the San Francisco-based firm that was an early investor in companies from Facebook to SpaceX.

With this new round of funding, Tribogenics will expedite time to market by hiring additional engineers and scientists as well as expanding the size of its internal R&D facility. The company plans to launch its lineup of small X-ray sources designed for new compact XRF devices in 2013 and is currently identifying key industry partners to co-develop the first commercial products based on this new technology.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.